SELLAS Reports Q2 2026 Results and Phase 3 GPS Update

SELLAS Life Sciences Group reported second quarter 2026 financial results and provided a corporate update. The company reported a net loss of $9.6 million ($0.05 per share) for the quarter, compared to $6.6 million ($0.07 per share) in the prior year period. Research and development expenses rose to $6.3 million, driven by manufacturing and clinical preparation for a potential Biologics License Application (BLA) for galinpepimut-S (GPS). SELLAS ended the quarter with a strong cash position of $138.3 million. Key clinical updates include the nearing of the 80th event in the Phase 3 REGAL trial of GPS in Acute Myeloid Leukemia (AML), which will trigger final efficacy analysis. Additionally, the company has enrolled 28 patients in its Phase 2 trial of SLS009 in newly diagnosed first-line AML, with topline data expected in Q4 2026. Preclinical data also suggests potential for SLS009 in advanced pancreatic cancer. Management highlighted that the current cash runway and trial progress support long-term value creation.